Novartis AG (0QLR) Price & Analysis

Compare

12 Followers

0QLR Stock Chart & Stats

CHF107.72

CHF0.25(0.27%)

At close: Jan 08 4:00 PM EST

CHF107.72

CHF0.25(0.27%)

Day’s Range― - ―

52-Week RangeCHF81.22 - CHF108.18

Previous CloseN/A

Volume210.36K

Average Volume (3M)1.02M

Market Cap

CHF206.54B

Enterprise ValueCHF208.96B

Total Cash (Recent Filing)CHF9.75B

Total Debt (Recent Filing)CHF32.02B

Price to Earnings (P/E)17.4

Beta0.78

Next Earnings

Feb 04, 2026

EPS Estimate

1.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.80

Shares Outstanding2,112,421,900

10 Day Avg. Volume801,914

30 Day Avg. Volume1,022,628

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)4.47

Price to Sales (P/S)3.81

P/FCF Ratio14.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF108.50

Price Target Upside0.72% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Pipeline AdvancementsThe company maintains a robust pipeline with several high-risk, high-reward projects expected to read out by 2026.

Product LaunchesNovartis is projected to have several successful product launches like Pluvicto, Scemblix, and Leqvio, with additional launches expected to strengthen its market position.

Sales Growth ForecastNovartis has upgraded its sales growth forecast with a new CAGR of 5-6%, implying higher future sales than previously expected.

Bears Say

Avidity Acquisition ImpactExpected earnings before interest and taxes (EBIT) might be impacted by dilution related to the Avidity acquisition.

Market FeedbackKOL feedback seems more cautious, describing the data as underwhelming and suggesting limited clinical use.

Valuation ConcernsDespite a promising pipeline and growth potential, the analyst maintains a Neutral rating on valuation, suggesting concerns over the stock's current price relative to its growth forecast.

Novartis AG News

Trump announces pacts with nine pharma companies to lower drug prices

U.S. President Donald J. Trump announced nine new agreements with major pharmaceutical companies to lower prescription drug prices...

1d ago

BMY

GSK

Novartis reaches agreement on lowering drug prices in U.S.

Novartis (NVS) announced it has reached an agreement with the U.S. government that aims to lower the price...

1d ago

NVS

Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports

At least seven drugmakers, including GlaxoSmithKline (GSK), Merck (MRK), and Sanofi (SNY), are expected to announce price cuts...

1d ago

AZN

BMY

Novartis treatment of myasthenia gravis granted orphan designation

Novartis (NVS) Pharmaceuticals’ iptacopan was granted FDA orphan designation as a treatment of myasthenia gravis, according to a...

1d ago

NVS

Top drugmakers to enter agreements with U.S. to cut drug prices, Reuters says

Several drugmakers are expected to announce agreements with the U.S. government to lower prescription drug prices, Michael Erman,...

1d ago

BMY

MRK

Avidity reports FTC granted request for early termination of HSR waiting period

In a regulatory filing, Avidity Biosciences (RNA) noted that as previously disclosed, the company entered into an Agreement...

2d ago

NVS

RNA

Novartis, Roche nearing drug price deals with U.S., Bloomberg says

The White House is set to announce drug pricing deals with pharmaceutical companies Novartis (NVS) and Roche (RHHBY)...

3d ago

NVS

CHRO

Salesforce Agentforce Life Sciences selected by Novartis

Salesforce (CRM) announced that Novartis (NVS) has selected Salesforce’s Agentforce Life Sciences for Customer Engagement to connect patient...

3d ago

CRM

NVS

Novartis breaks ground on North Carolina manufacturing hub

Novartis (NVS) broke ground yesterday on its more than 700,000-square-foot flagship manufacturing hub in North Carolina, moving rapidly...

8d ago

NVS

Novartis price target raised to $112 from $106 at HSBC

HSBC raised the firm’s price target on Novartis (NVS) to $112 from $106 and keeps a Reduce rating...

10d ago

NVS

Novartis AG: Strong Growth Potential and Strategic Innovations Justify Buy Rating

Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on NOVN stock, giving a Buy...

5d ago

NVS

Novartis AG: Strong Growth Potential Amid Patent Expirations with Robust Pipeline and Strategic Phase III Trials

In a report released today, Sachin Jain from Bank of America Securities upgraded Novartis AG to a Buy,...

26d ago

NVS

Novartis AG: Hold Rating Amid Moderate Growth and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities reiterated a Hold rating on Novartis AG, retaining the price...

1M ago

NVS

Cautious Hold on Novartis AG Amid Mixed Ianalumab Data and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novartis AG, retaining the price...

2M ago

NVS

0QLR FAQ

What was Novartis AG’s price range in the past 12 months?

Novartis AG lowest share price was CHF81.22 and its highest was CHF108.18 in the past 12 months.

What is Novartis AG’s market cap?

Novartis AG’s market cap is CHF206.54B.

When is Novartis AG’s upcoming earnings report date?

Novartis AG’s upcoming earnings report date is Feb 04, 2026 which is in 46 days.

How were Novartis AG’s earnings last quarter?

Novartis AG released its earnings results on Oct 28, 2025. The company reported CHF1.797 earnings per share for the quarter, missing the consensus estimate of CHF1.816 by -CHF0.018.

Is Novartis AG overvalued?

According to Wall Street analysts Novartis AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novartis AG pay dividends?

Novartis AG does not currently pay dividends.

What is Novartis AG’s EPS estimate?

Novartis AG’s EPS estimate is 1.57.

How many shares outstanding does Novartis AG have?

Novartis AG has 2,112,421,900 shares outstanding.

What happened to Novartis AG’s price movement after its last earnings report?

Novartis AG reported an EPS of CHF1.797 in its last earnings report, missing expectations of CHF1.816. Following the earnings report the stock price went down -3.255%.

Which hedge fund is a major shareholder of Novartis AG?

Currently, no hedge funds are holding shares in GB:0QLR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG (0QLR) Earnings & Revenues

Historic Earnings Reports

0QLR Stock 12 Month Forecast

Average Price Target

CHF108.50

▲(0.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","105":"CHF105","126":"CHF126","94.5":"CHF94.5","115.5":"CHF115.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF108.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,94.5,105,115.5,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.5,106.07692307692308,107.65384615384616,109.23076923076923,110.8076923076923,112.38461538461539,113.96153846153847,115.53846153846153,117.11538461538461,118.6923076923077,120.26923076923077,121.84615384615384,123.42307692307692,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.5,104.8076923076923,105.11538461538461,105.42307692307692,105.73076923076923,106.03846153846153,106.34615384615384,106.65384615384616,106.96153846153847,107.26923076923077,107.57692307692308,107.88461538461539,108.1923076923077,{"y":108.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.5,103.38461538461539,102.26923076923077,101.15384615384616,100.03846153846153,98.92307692307692,97.8076923076923,96.6923076923077,95.57692307692308,94.46153846153847,93.34615384615384,92.23076923076923,91.11538461538461,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.974,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.508,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.266,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.147,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.695,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.747,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.815,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.469,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.334,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.428,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >